HilleVax, Inc.

NASDAQ:HLVX

1.91 (USD) • At close November 8, 2024
Bedrijfsnaam HilleVax, Inc.
Symbool HLVX
Munteenheid USD
Prijs 1.91
Beurswaarde 95,089,235
Dividendpercentage 0%
52-weken bereik 1.55 - 20.22
Industrie Biotechnology
Sector Healthcare
CEO Dr. Robert M. Hershberg M.D., Ph.D.
Website https://www.hillevax.com

An error occurred while fetching data.

Over HilleVax, Inc.

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Vergelijkbare Aandelen

Rigel Pharmaceuticals, Inc. logo

Rigel Pharmaceuticals, Inc.

RIGL

22.07 USD

C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc.

CCCC

6.06 USD

EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc.

EYPT

11.63 USD

Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc.

HRTX

1.75 USD

Absci Corporation logo

Absci Corporation

ABSI

4.07 USD

OraSure Technologies, Inc. logo

OraSure Technologies, Inc.

OSUR

4.29 USD

Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc.

FULC

3.49 USD

Athira Pharma, Inc. logo

Athira Pharma, Inc.

ATHA

0.66 USD

ALX Oncology Holdings Inc. logo

ALX Oncology Holdings Inc.

ALXO

1.45 USD

BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc.

BTAI

0.68 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)